These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 16545436)

  • 1. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL; Allison JM; Shimizu Y; ElShamy WM
    Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
    Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D
    Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S; Choi EJ; Jin C; Kim DH
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.
    Singh M; Chaudhry P; Fabi F; Asselin E
    BMC Cancer; 2013 May; 13():233. PubMed ID: 23663432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
    Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
    Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells].
    Zhou Y; Wang SY; Yang XK; Wang HM
    Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):97-100. PubMed ID: 21575475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
    Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
    Selvendiran K; Tong L; Vishwanath S; Bratasz A; Trigg NJ; Kutala VK; Hideg K; Kuppusamy P
    J Biol Chem; 2007 Sep; 282(39):28609-28618. PubMed ID: 17684018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
    Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
    Woo MG; Xue K; Liu J; McBride H; Tsang BK
    J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.
    Gong J; Xing C; Wang LY; Xie SS; Xiong WD
    J BUON; 2019; 24(2):701-708. PubMed ID: 31128026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin.
    Arimoto-Ishida E; Ohmichi M; Mabuchi S; Takahashi T; Ohshima C; Hayakawa J; Kimura A; Takahashi K; Nishio Y; Sakata M; Kurachi H; Tasaka K; Murata Y
    Endocrinology; 2004 Apr; 145(4):2014-22. PubMed ID: 14701673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
    Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
    Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.